SEATTLE, WA, March 29, 2018 (GLOBE NEWSWIRE) -- Cannabis Leaf, Inc., a developer of cutting-edge medical products,
nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry, announces today that on March
4, 2018, an Agreement for Plan of Merger was entered in by Cannabis Leaf, Inc. and Apotheca Biosciences, Inc., with the surviving
Corporation to be Apotheca Biosciences.
Apotheca Biosciences and Cannabis Leaf entered into the Merger Agreement where Cannabis Leaf agreed to deliver to Apotheca
Biosciences a certain issuance of sixty million (60,000,000) common shares of Cannabis Leaf, Inc. (the “Exchange Shares”), in
exchange for all shares of Apotheca Biosciences being acquired into Cannabis Leaf, which would result in a change in control of
Cannabis Leaf with such issuance. The issuance will result in Apotheca Biosciences being the surviving company under the laws of
the State of Nevada. Under the Agreement, upon closing, Apotheca Biosciences will receive the immediate right to appointment of the
directors and officers of the surviving company by the resignation of the existing director and officer of Cannabis Leaf, with the
simultaneous appointment of two directors and officers being appointed by Apotheca. The issuance of the 60,000,000 common
shares of Cannabis Leaf will represent the controlling interest of Cannabis Leaf, Inc. after such merger occurs.
Additionally, the Parties have agreed to change the name of Cannabis Leaf, Inc. to Apotheca Biosciences, Inc. under Nevada
law.
Apotheca Biosciences is developing cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the
healthcare and consumer care industry. Their pipeline of products includes, transdermal, sublingual, and nasal delivery
technologies for precise and controlled dosing of cannabinoids.
Apotheca Biosciences is a pioneering biotech company with an emphasis on research and development in addition to the creation of
high-grade nutraceuticals and cosmetics. Apothecia’s’ goal is to lay the groundwork and continue research of cannabinoid
receptiveness in patients and create nutraceuticals that reflects their research.
More information on Apotheca Biosciences can be found at: http://www.apothecabiosciences.com/
The Parties project the formal closing for the transaction to occur by end of March 2018, with issuance of the control block of
shares, change of directors and officers, and resolution for the name change as required under Nevada law. The Company will file a
combined audited financial statement under SEC guidelines.
About Apotheca Biosciences
Apotheca Biosciences is a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for
the healthcare and consumer care industry. Our pipeline of products includes, transdermal, sublingual, and nasal delivery
technologies for precise and controlled dosing of cannabinoids. We believe that we can deliver meaningful benefits using our
technologies to the world’s aging population.
To request further information about Apotheca, please email us at info@apothecabiosciences.com, log onto our website at
http://www.apothecabiosciences.com/, or visit us on FB @apotheca and Twitter @apotheca
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement
of our services and products, statements about future market conditions, supply and demand conditions, and other expectations,
intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our
expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce
today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar
expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a
number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This
release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the
Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking
statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may
differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation,
ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Contact: Jason Sakowski Media Contact : 206.430.6250 Apotheca Biosciences http://www. apothecabiosciences.com info@apothecabiosciences.com Twitter - @apotheca Facebook - apotheca
